A Global, Phase 1/2, Open-label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia

Administered By

Awarded By

Contributors

Start/End

  • February 12, 2021 - April 30, 2024